- Home
- SKWD vs ARQT Comparison
SKWD vs ARQT Comparison
Compare SKWD & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SKWD | ARQT |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | 611 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.2B |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SKWD | ARQT |
|---|---|---|
| Price | $60.59 | $32.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 8 |
| Target Price | ★ $70.73 | $38.38 |
| AVG Volume (30 Days) | 309.5K | ★ 2.0M |
| Earning Date | 11-05-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 41.81 | ★ 88.79 |
| EPS | ★ 2.17 | 0.03 |
| Revenue | ★ $1,416,541,000.00 | $376,072,000.00 |
| Revenue This Year | $39.34 | $43.01 |
| Revenue Next Year | $6.68 | $27.70 |
| P/E Ratio | ★ $28.14 | $961.17 |
| Revenue Growth | 23.16 | ★ 91.34 |
| 52 Week Low | $40.60 | $19.30 |
| 52 Week High | $65.69 | $31.77 |
Technical Indicators
Market Signals| Indicator | SKWD | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 65.66 | 74.70 |
| Support Level | $55.18 | $24.91 |
| Resistance Level | $63.49 | N/A |
| Average True Range (ATR) | 1.41 | 1.38 |
| MACD | 0.61 | 0.61 |
| Stochastic Oscillator | 92.94 | 99.07 |
Price Performance
Historical ComparisonAbout SKWD Skyward Specialty Insurance Group Inc.
Skyward Specialty Insurance Group Inc is a specialty insurance company that offers a suite of specialized insurance solutions across specialty property and casualty markets on a non-admitted and admitted basis. Its portfolio of insurance offerings covers a wide variety of risks, including general liability, commercial auto, group accident and health, property, agriculture, credit, surety, and workers' compensation, among others. Geographically, the group mainly operates in the United States.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.